MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study-Reference-Cited by-同舟云学术

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Published:2013-03 Issue:3 Volume:14 Page:249-256
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ascierto Paolo A,Schadendorf Dirk,Berking Carola,Agarwala Sanjiv S,van Herpen Carla ML,Queirolo Paola,Blank Christian U,Hauschild Axel,Beck J Thaddeus,St-Pierre Annie,Niazi Faiz,Wandel Simon,Peters Malte,Zubel Angela,Dummer Reinhard

Publisher

Elsevier BV

Subject

Oncology

Reference42 articles.

1. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A);Hill;Cancer,1984

2. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J Clin Oncol,1999

3. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma;Middleton;J Clin Oncol,2000

4. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032);Patel;Eur J Cancer,2011

5. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

Cited by 586 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A NRAS mRNA G-quadruplex structure-targeting small-molecule ligand reactivating DNA damage response in human cancer cells for combination therapy with clinical PI3K inhibitors;International Journal of Biological Macromolecules;2024-11

2. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting;Melanoma Research;2024-08-30

3. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

4. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

5. The safety and efficacy of binimetinib for lung cancer: a systematic review;BMC Pulmonary Medicine;2024-08-01